Please check your internet connection and try again.
# Hepa-Merz (L-Ornithine L-Aspartate / LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids that serves as a substrate for the urea cycle and glutamine synthesis. It is used to accelerate the detoxification of ammonia in patients with hyperammonemia associated with liver disease.
## Primary Indications
* Management of hyperammonemia in liver cirrhosis.
* Adjunctive therapy for hepatic encephalopathy (HE).
## Adult Dosing
* **Oral (Granules):** 3 g (one sachet) up to 3 times daily, dissolved in fluid, taken after meals.
* **Intravenous (Severe cases/acute episodes):** 4–8 ampoules (40–80 g) daily as a continuous infusion.
* **Max IV dose:** Do not exceed 5 g per hour via IV drip.
## Pediatric Dosing
* **Safety/Efficacy:** Not well-established in pediatric populations. Use is generally discouraged unless directed by a specialist in a hepatology setting. No standard weight-based pediatric dosing exists.
## Dose Adjustments
* **Renal Impairment:** Reduce dose in severe renal insufficiency (serum creatinine > 3 mg/dL) due to limited clearance data.
* **Hepatic Impairment:** No dose reduction necessary; however, monitor ammonia levels.
## Contraindications
* Hypersensitivity to the active ingredients.
* Advanced renal failure (serum creatinine > 3 mg/dL).
* Severe methylmalonic acidemia (theoretical, related to pathway metabolism).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain.
* **Rare:** Extremity pain, dizziness, pruritus/rash.
* **Serious:** Potential for infusion-site reactions or metabolic disturbances if infused too rapidly.
## Key Drug Interactions
* No major clinical "black box" herb-drug/drug-drug interactions currently documented.
* Caution when combining with other CNS-depressant drugs (e.g., lactulose, rifaximin) as clinical efficacy overlap complicates patient monitoring.
## Monitoring
* Serum ammonia levels (pre- and post-treatment to assess efficacy).
* Liver function tests (ALT, AST, Bilirubin).
* Renal function (BUN/Creatinine) in patients at risk of accumulation.
* Mental status/Clinical neurological examinations.
## Clinical Pearls
* **Solubility:** Ensure granules are completely dissolved in fluids (e.g., tea, juice) prior to ingestion.
* **Lactulose Synergy:** LOLA is often used as an adjunct to, not a replacement for, lactulose in the management of HE.
* **IV Administration:** Must be diluted (e.g., in saline or D5W); do not inject undiluted ampoules directly into the vein due to osmolarity and potential for irritation.
* **Evidence Status:** While widely used in Europe and Asia, clinical evidence for HE remains heterogeneous. Meta-analyses suggest benefit in reducing ammonia, but strict adherence to standard of care (lactulose/rifaximin) is priority.
***
**Disclaimer:** This information is for educational purposes only. Dosing protocols may vary by hospital policy or regional guidelines. Always verify current prescribing information in your local formulary or with the manufacturer's package insert before administration. Consult a specialist for complex hepatology cases.
